SMRITI KRISHNA

Dr. SMRITI KRISHNA

James Cook University
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
SMRITI KRISHNASMRITI KRISHNA
SMRITI KRISHNA
SSSai Wang Seto
Sai Wang Seto
RJRoby J. Jose
Roby J. Jose
JLJiaze Li
Jiaze Li
SMSusan K. Morton
Susan K. Morton
Jonathan GolledgeJonathan Golledge
Jonathan Golledge
Objective—: Sclerostin (SOST) has been identified as an important regulator of bone formation; however, it has not been previously implicated in arterial disease. The aim of this study was to assess the role of SOST in aortic aneurysm (AA) and atherosclerosis using human samples, a mouse model, and in vitro investigations. Approach and Results—: SOST protein was downregulated in human and mouse AA samples compared with controls. Transgenic introduction of human SOST in apolipoprotein E–deficient ( ApoE −/− ) mice ( SOST Tg . ApoE −/− ) and administration of recombinant mouse Sost inhibited angiotensin II–induced AA and atherosclerosis. Serum concentrations of several proinflammatory cytokines were significantly reduced in SOST Tg . ApoE −/− mice. Compared with controls, the aortas of mice receiving recombinant mouse Sost and SOST Tg . ApoE −/− mice showed reduced matrix degradation, reduced elastin breaks, and preserved collagen. Decreased inflammatory cell infiltration and a reduction in the expression of wingless-type mouse mammary virus integration site/β-catenin responsive genes, including matrix metalloproteinase-9, osteoprotegerin, and osteopontin, were observed in the aortas of SOST Tg . ApoE −/− mice. SOST expression was downregulated and the wingless-type mouse mammary virus integration site/β-catenin pathway was activated in human AA samples. The cytosine–phosphate–guanine islands in the SOST gene promoter showed significantly higher methylation in human AA samples compared with controls. Incubation of vascular smooth muscle cells with the demethylating agent 5-azacytidine resulted in upregulation of SOST, suggesting that SOST is epigenetically regulated. Conclusions—: This study identifies that SOST is expressed in the aorta and downregulated in human AA possibly because of epigenetic silencing. Upregulating SOST inhibits AA and atherosclerosis development, with potential important implications for treating these vascular diseases.

Verified
Journal Article
Open access
PDF file
SMRITI KRISHNASMRITI KRISHNA
SMRITI KRISHNA
Joe MoxonJoe Moxon
Joe Moxon
Jonathan GolledgeJonathan Golledge
Jonathan Golledge
Peripheral artery disease (PAD) is due to the blockage of the arteries supplying blood to the lower limbs usually secondary to atherosclerosis. The most severe clinical manifestation of PAD is critical limb ischemia (CLI), which is associated with a risk of limb loss and mortality due to cardiovascular events. Currently CLI is mainly treated by surgical or endovascular revascularization, with few other treatments in routine clinical practice. There are a number of problems with current PAD management strategies, such as the difficulty in selecting the appropriate treatments for individual patients. Many patients undergo repeated attempts at revascularization surgery, but ultimately require an amputation. There is great interest in developing new methods to identify patients who are unlikely to benefit from revascularization and to improve management of patients unsuitable for surgery. Circulating biomarkers that predict the progression of PAD and the response to therapies could assist in the management of patients. This review provides an overview of the pathophysiology of PAD and examines the association between circulating biomarkers and PAD presence, severity and prognosis. While some currently identified circulating markers show promise, further larger studies focused on the clinical value of the biomarkers over existing risk predictors are needed.

1 January 2013 in Atherosclerosis
Verified
Journal Article
Closed access
Yutang WangYutang Wang
Yutang Wang
SMRITI KRISHNASMRITI KRISHNA
SMRITI KRISHNA
Jonathan GolledgeJonathan Golledge
Jonathan Golledge

1 August 2012 in The American Journal of Pathology
Verified
Journal Article
Closed access
SMRITI KRISHNASMRITI KRISHNA
SMRITI KRISHNA
SSSai Wang Seto
Sai Wang Seto
Joe MoxonJoe Moxon
Joe Moxon
CRCatherine Rush
Catherine Rush
PWPhilip J. Walker
Philip J. Walker
Jonathan GolledgeJonathan Golledge
Jonathan Golledge

1 June 2013 in Atherosclerosis
Verified
Journal Article
Closed access
SMRITI KRISHNASMRITI KRISHNA
SMRITI KRISHNA
ADAnthony E. Dear
Anthony E. Dear
JCJeffrey M. Craig
Jeffrey M. Craig
PNPaul E. Norman
Paul E. Norman
Jonathan GolledgeJonathan Golledge
Jonathan Golledge

1 January 2006 in Virus Research
Verified
Journal Article
Closed access
SMRITI KRISHNASMRITI KRISHNA
SMRITI KRISHNA
SJSusan James
Susan James
PBPrabha Balaram
Prabha Balaram